Dr. Reddy’s Laboratories has postponed supplies of its semaglutide products after detecting a quality issue with the active pharmaceutical ingredient (API), a move that is expected to delay planned deliveries and has weighed on investor sentiment.
The company said the issue was identified during routine quality checks involving a batch of the API used to manufacture semaglutide. While the problem does not involve the finished medicine already in circulation, Dr. Reddy’s has decided to hold back fresh supplies until the ingredient meets all required quality standards.
Semaglutide is one of the world’s fastest-growing medicines, widely used to treat type 2 diabetes and increasingly prescribed for weight management. The strong global demand for the drug has encouraged several pharmaceutical companies, including Dr. Reddy’s, to expand production and prepare for new market opportunities.
The company has not specified when supplies will resume but said it is working to resolve the issue as quickly as possible. It also reaffirmed that maintaining product quality and patient safety remains its highest priority.
The announcement affected investor confidence, with Dr. Reddy’s shares declining after the update. Market participants are assessing the possible impact on the company’s near-term revenue from semaglutide, although analysts believe the delay is precautionary and reflects the company’s adherence to strict manufacturing standards.
Experts say pharmaceutical companies often pause production or shipments when quality concerns arise, as regulatory compliance requires every batch to meet rigorous safety and efficacy standards before reaching patients. Such steps, while temporarily affecting business, help protect long-term credibility and regulatory trust.
Dr. Reddy’s has clarified that the issue is limited to the affected API batch and has not indicated any wider impact on its other medicines or manufacturing operations. The company will restart supplies once replacement material successfully clears all quality tests.
The temporary delay comes as the pharmaceutical industry races to meet soaring global demand for semaglutide-based therapies, making uninterrupted production increasingly important.
Also Read: RBI rolls out three key economic surveys
